UTHR

SEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 11

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,632

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

F9 · price: This transaction was executed in multiple trades at prices ranging from $334.155 to $334.87. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 10

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,730

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

SEC source: 0001415889-24-020431 · form4-07312024_040703.xml · derivative · entry 24

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,669

Underlying: Common Stock · 3,600 shares

Expires 2024-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

SEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 9

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 130

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

SEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 8

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 255

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

F8 · price: This transaction was executed in multiple trades at prices ranging from $339.05 to $339.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 7

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 676

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

F7 · price: This transaction was executed in multiple trades at prices ranging from $337.67 to $338.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 6

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 923

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

F6 · price: This transaction was executed in multiple trades at prices ranging from $336.615 to $337.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 5

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,258

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

F5 · price: This transaction was executed in multiple trades at prices ranging from $335.56 to $336.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 4

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,710

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

F4 · price: This transaction was executed in multiple trades at prices ranging from $334.425 to $335.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 3

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,512

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

F3 · price: This transaction was executed in multiple trades at prices ranging from $333.385 to $334.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 2

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,501

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $332.315 to $333.155. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-020431 · form4-07312024_040703.xml · nonDerivative · entry 1

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,730

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

SEC source: 0001415889-24-020249 · form4-07292024_040701.xml · derivative · entry 24

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 72,269

Underlying: Common Stock · 3,600 shares

Expires 2024-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

SEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 16

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 130

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

F15 · price: This transaction was executed in multiple trades at prices ranging from $339.57 to $340.135. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 15

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,080

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

F14 · price: This transaction was executed in multiple trades at prices ranging from $338.57 to $339.565. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 14

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,195

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

F13 · price: This transaction was executed in multiple trades at prices ranging from $337.38 to $338.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 13

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,918

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

F12 · price: This transaction was executed in multiple trades at prices ranging from $336.37 to $337.36. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 12

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,730

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

SEC source: 0001415889-24-020164 · form4-07262024_040707.xml · derivative · entry 2

KURZWEIL RAY · CIK 0001108501 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 590

Underlying: Common Stock · 590 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F1 · shares: Annual non-employee director award.

F2 · derivative.exercise_date: These awards vest on the one-year anniversary of the grant date.

F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date.

SEC source: 0001415889-24-020164 · form4-07262024_040707.xml · derivative · entry 1

KURZWEIL RAY · CIK 0001108501 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,440

Underlying: Common Stock · 1,440 shares

Expires 2034-07-25

F1 · shares: Annual non-employee director award.

F2 · derivative.exercise_date: These awards vest on the one-year anniversary of the grant date.

SEC source: 0001415889-24-020174 · form4-07262024_040731.xml · derivative · entry 1

Olian Judy D. · CIK 0001605729 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,190

Underlying: Common Stock · 1,190 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F2 · shares: Annual non-employee director award.

F3 · derivative.exercise_date: These awards vest on the one-year anniversary of the grant date.

F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date.

SEC source: 0001415889-24-020173 · form4-07262024_040728.xml · derivative · entry 1

Giltner Richard · CIK 0001460472 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,190

Underlying: Common Stock · 1,190 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F2 · shares: Annual non-employee director award.

F3 · derivative.exercise_date: These awards vest on the one-year anniversary of the grant date.

F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date.

SEC source: 0001415889-24-020172 · form4-07262024_040725.xml · derivative · entry 1

CAUSEY CHRISTOPHER · CIK 0001237334 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,190

Underlying: Common Stock · 1,190 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F2 · shares: Annual non-employee director award.

F3 · derivative.exercise_date: These awards vest on the one-year anniversary of the grant date.

F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date.

SEC source: 0001415889-24-020171 · form4-07262024_040722.xml · derivative · entry 1

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,890

Underlying: Common Stock · 2,890 shares

Expires 2034-07-25

F1 · shares: Annual non-employee director award.

F2 · derivative.exercise_date: These awards vest on the one-year anniversary of the grant date.

SEC source: 0001415889-24-020169 · form4-07262024_040719.xml · derivative · entry 2

SULLIVAN LOUIS W · CIK 0001193522 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 590

Underlying: Common Stock · 590 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F1 · shares: Annual non-employee director award.

F2 · derivative.exercise_date: These awards vest on the one-year anniversary of the grant date.

F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date.

SEC source: 0001415889-24-020169 · form4-07262024_040719.xml · derivative · entry 1

SULLIVAN LOUIS W · CIK 0001193522 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,440

Underlying: Common Stock · 1,440 shares

Expires 2034-07-25

F1 · shares: Annual non-employee director award.

F2 · derivative.exercise_date: These awards vest on the one-year anniversary of the grant date.

SEC source: 0001415889-24-020168 · form4-07262024_040717.xml · derivative · entry 1

MAXWELL LINDA · CIK 0001822674 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,890

Underlying: Common Stock · 2,890 shares

Expires 2034-07-25

F1 · shares: Annual non-employee director award.

F2 · derivative.exercise_date: These awards vest on the one-year anniversary of the grant date.

SEC source: 0001415889-24-020167 · form4-07262024_040715.xml · derivative · entry 2

PATUSKY CHRISTOPHER · CIK 0001231427 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 590

Underlying: Common Stock · 590 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F1 · shares: Annual non-employee director award.

F2 · derivative.exercise_date: These awards vest on the one-year anniversary of the grant date.

F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date.

SEC source: 0001415889-24-020167 · form4-07262024_040715.xml · derivative · entry 1

PATUSKY CHRISTOPHER · CIK 0001231427 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,440

Underlying: Common Stock · 1,440 shares

Expires 2034-07-25

F1 · shares: Annual non-employee director award.

F2 · derivative.exercise_date: These awards vest on the one-year anniversary of the grant date.

SEC source: 0001415889-24-020166 · form4-07262024_040713.xml · derivative · entry 2

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 590

Underlying: Common Stock · 590 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F1 · shares: Annual non-employee director award.

F2 · derivative.exercise_date: These awards vest on the one-year anniversary of the grant date.

F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date.

SEC source: 0001415889-24-020166 · form4-07262024_040713.xml · derivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,440

Underlying: Common Stock · 1,440 shares

Expires 2034-07-25

F1 · shares: Annual non-employee director award.

F2 · derivative.exercise_date: These awards vest on the one-year anniversary of the grant date.

SEC source: 0001415889-24-020165 · form4-07262024_040709.xml · derivative · entry 2

MALCOLM JAN · CIK 0002028640 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 590

Underlying: Common Stock · 590 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F1 · shares: Annual non-employee director award.

F2 · derivative.exercise_date: These awards vest on the one-year anniversary of the grant date.

F4 · derivative.expiration_date: Not applicable as restricted stock units do not have an expiration date.

SEC source: 0001415889-24-020165 · form4-07262024_040709.xml · derivative · entry 1

MALCOLM JAN · CIK 0002028640 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,440

Underlying: Common Stock · 1,440 shares

Expires 2034-07-25

F1 · shares: Annual non-employee director award.

F2 · derivative.exercise_date: These awards vest on the one-year anniversary of the grant date.

SEC source: 0001415889-24-020163 · form4-07262024_040703.xml · derivative · entry 1

DWEK RAYMOND · CIK 0001231617 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,890

Underlying: Common Stock · 2,890 shares

Expires 2034-07-25

F1 · shares: Annual non-employee director award.

F2 · derivative.exercise_date: These awards vest on the one-year anniversary of the grant date.

SEC source: 0001415889-24-020249 · form4-07292024_040701.xml · derivative · entry 23

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 75,869

Underlying: Common Stock · 3,600 shares

Expires 2024-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

SEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 11

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 130

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

F11 · price: This transaction was executed in multiple trades at prices ranging from $343.435 to $343.87. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 10

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 220

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

F10 · price: This transaction was executed in multiple trades at prices ranging from $342.32 to $343.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 9

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 464

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

F9 · price: This transaction was executed in multiple trades at prices ranging from $341.22 to $342.095. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 8

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,188

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

F8 · price: This transaction was executed in multiple trades at prices ranging from $340.15 to $340.825. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 7

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,719

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

F7 · price: This transaction was executed in multiple trades at prices ranging from $339.66 to $340.065. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 6

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,016

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

F6 · price: This transaction was executed in multiple trades at prices ranging from $338.63 to $339.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 5

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,021

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

F5 · price: This transaction was executed in multiple trades at prices ranging from $337.475 to $338.075. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 4

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,235

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

F4 · price: This transaction was executed in multiple trades at prices ranging from $336.375 to $337.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 3

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,011

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

F3 · price: This transaction was executed in multiple trades at prices ranging from $335.36 to $336.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 2

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,600

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $333.73 to $334.015. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-020249 · form4-07292024_040701.xml · nonDerivative · entry 1

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,730

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

SEC source: 0001415889-24-020102 · form4-07252024_040701.xml · derivative · entry 22

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 79,469

Underlying: Common Stock · 3,600 shares

Expires 2024-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

SEC source: 0001415889-24-020102 · form4-07252024_040701.xml · nonDerivative · entry 14

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 130

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

F11 · price: This transaction was executed in multiple trades at prices ranging from $336.59 to $337.525. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-020102 · form4-07252024_040701.xml · nonDerivative · entry 13

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 293

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

F10 · price: This transaction was executed in multiple trades at prices ranging from $335.47 to $336.28. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-24-020102 · form4-07252024_040701.xml · nonDerivative · entry 12

ROTHBLATT MARTINE A · CIK 0001106578 · Director · Chairperson & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 989

F1 · kind: This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on August 4, 2023. This plan will continue until the earlier of: (a) exhaustion of a tranche of 723,869 stock options that expire December 31, 2024; or (b) August 31, 2024.

F9 · price: This transaction was executed in multiple trades at prices ranging from $334.38 to $335.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.